Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.66 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772360 | 0.86 | PDGFRB (0.77) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL32667946 | 0.86 | PDGFRB (0.77) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL708999 | 0.84 | PDGFRB (0.75) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL26829682 | 0.82 | PDGFRB (0.72) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL29375510 | 0.82 | PDGFRB (0.72) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL24621829 | 0.82 | PDGFRB (0.72) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL12074709 | 0.81 | PDGFRB (0.70) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL7260960 | 0.81 | CYP2A6 (0.57) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL2346887 | 0.79 | PDGFRB (1.00) | PDGFRBPDGFRACYP2A6BIRC5CA12 | |
| SCHEMBL1928138 | 0.79 | PDGFRB (0.49) | PDGFRBPDGFRACYP2A6BIRC5CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112912372-A | Cyclic azine compound, material for organic electroluminescent element, electron transport material for organic electroluminescent element, and organic electroluminescent element | 东曹株式会社 | 2021-06-04 | — | — | CN | claimed |
| WO-2003051879-A1 | KNOWN AND NOVEL 4,5-DIHYDRO-IMIDAZO[4,5,1-IJ]QUINOLIN-6-ONES USEFUL AS POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | claimed |
| EP-0674635-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1995-10-04 | — | — | EP | claimed |
| WO-1994014803-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-07-07 | — | — | WO | claimed |
| CN-109311844-B | Triazine compound, method for producing same, and organic electroluminescent element containing same as constituent component | 东曹株式会社 | 2021-07-20 | — | — | CN | disclosed |
| CN-112912372-A | Cyclic azine compound, material for organic electroluminescent element, electron transport material for organic electroluminescent element, and organic electroluminescent element | 东曹株式会社 | 2021-06-04 | — | — | CN | disclosed |
| WO-2020085319-A1 | CYCLIC AZINE COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ELECTRON TRANSPORT MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, AND ORGANIC ELECTROLUMINESCENT ELEMENT | 東ソー株式会社 | 2020-04-30 | — | — | WO | disclosed |
| WO-2019163959-A1 | CYCLIC AZINE COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCNET ELEMENT, AND ELECTRON-TRANSPORTING MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT | 東ソー株式会社 | 2019-08-29 | — | — | WO | disclosed |
| US-10243151-B2 | Organic semiconductor material and light-emitting element, light-emitting device, lighting system, and electronic device using the same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2019-03-26 | — | — | US | disclosed |
| CN-109311844-A | Triaizine compounds, its manufacturing method and the organic electroluminescent device as constituent | 东曹株式会社 | 2019-02-05 | — | — | CN | disclosed |
| US-20170250352-A1 | Organic Semiconductor Material and Light-Emitting Element, Light-Emitting Device, Lighting System, and Electronic Device Using the Same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| CN-106573912-A | Triazine compound, method for producing same, and application for same | 东曹株式会社 | 2017-04-19 | — | — | CN | disclosed |
| EP-1482924-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-05-21 | — | — | EP | disclosed |
| US-7375134-B2 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | AXYS PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2005-10-27 | — | — | US | disclosed |
| CN-1638757-A | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA INC (CA) | 2005-07-13 | — | — | CN | disclosed |
| WO-2003051879-A1 | KNOWN AND NOVEL 4,5-DIHYDRO-IMIDAZO[4,5,1-IJ]QUINOLIN-6-ONES USEFUL AS POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | disclosed |
| EP-0674635-B1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | SYNGENTA LTD (GB) | 2001-03-28 | — | — | EP | disclosed |
| EP-0674635-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014803-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10243151-B2 | Organic semiconductor material and light-emitting element, light-emitting device, lighting system, and electronic device using the same | OXA1L, BECN1, MAP1LC3A | PDGFRB 4755/4885PDGFRA 4340/4885CYP2A6 2166/4885 |
| US-20170250352-A1 | Organic Semiconductor Material and Light-Emitting Element, Light-Emitting Device, Lighting System, and Electronic Device Using the Same | OXA1L, BECN1, MAP1LC3A | PDGFRB 4755/4885PDGFRA 4340/4885CYP2A6 2166/4885 |
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | CTSE, CTSS, CTSB | PDGFRB 885/4885PDGFRA 1966/4885CYP2A6 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.